Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 13/20 | 1.00 |
| ▸ | JAK2 | O60674 | 11/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20400446 | 1.00 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL30018491 | 1.00 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL30018897 | 1.00 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL20400442 | 1.00 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL20399738 | 0.97 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL20399654 | 0.97 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL30018447 | 0.97 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL20399653 | 0.97 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL30018823 | 0.97 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL20399394 | 0.94 | JAK1 (1.00) | JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2026-01-29 | — | — | US | claimed |
| CN-115925693-A | Selective inhibitors of JAK1 | 阿斯利康(瑞典)有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-110461830-B | Selective inhibitors of JAK1 | 阿斯利康(瑞典)有限公司 | 2022-11-01 | — | — | CN | claimed |
| US-10961228-B2 | JAK1 selective inhibitors | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | claimed |
| WO-2018134213-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2018-07-26 | — | — | WO | claimed |
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2026-01-29 | — | — | US | disclosed |
| US-12473272-B2 | JAK1 selective inhibitors | ASTRAZENECA AB (SE) | 2025-11-18 | — | — | US | disclosed |
| US-20240208947-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208947-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-27 | — | — | US | disclosed |
| US-11897869-B2 | JAK1 selective inhibitors | ASTAZENECA AB (SE) | 2024-02-13 | — | — | US | disclosed |
| EP-4219470-A1 | JAK1 SELECTIVE INHIBITORS | Astrazeneca AB (SE) | 2023-08-02 | — | — | EP | disclosed |
| CN-115925693-A | Selective inhibitors of JAK1 | 阿斯利康(瑞典)有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-3571192-B1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2022-11-30 | — | — | EP | disclosed |
| CN-110461830-B | Selective inhibitors of JAK1 | 阿斯利康(瑞典)有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20210188821-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA PHARMACEUTICALS LP | 2021-06-24 | — | — | US | disclosed |
| US-20210188821-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA PHARMACEUTICALS LP | 2021-06-24 | — | — | US | disclosed |
| US-10961228-B2 | JAK1 selective inhibitors | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | disclosed |
| US-10961228-B2 | JAK1 selective inhibitors | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | disclosed |
| WO-2018134213-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018134213-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473272-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885 |
| US-11897869-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885 |
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885 |
| US-20240208947-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885 |
| US-20210188821-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885 |
| US-10961228-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.